ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Extralabel drug use in animals. 21 CFR 530.
-
2. Sundlof SF, Kaneene JB, Miller RA. National survey on veterinarian-initiated drug use in lactating dairy cows. J Am Vet Med Assoc 1995; 207: 347–352.
-
3. Espinasse J, Thouvenot JP, Dalle S, et al. Comparative study of the action of flunixin meglumine and tolfenamic acid on prostaglandinE2 synthesis in bovine inflammatory exudate. J Vet Pharmacol Ther 1994; 17:271–274.
-
4. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104(suppl 3A):2S–8S.
-
5. USDA Food Safety and Inspection Service. United States national residue program for meat, poultry, and egg products. 2011 residue sample results. Available at: www.fsis.usda.gov/wps/wcm/connect/f511ad0e-d148-4bec-95c7-22774e731f7c/2011_Red_Book.pdf?MOD=AJPERES. Accessed Feb 13, 2015.
-
6. USDA Food Safety and Inspection Service. United States national residue program for meat, poultry, and egg products. 2012 residue sample results. Available at: www.fsis.usda.gov/wps/wcm/connect/be77fe0d-2295-417f-9472-6b43052068b9/2012-Red-Book.pdf?MOD=AJPERES. Accessed Feb 13, 2015.
-
7. Kissell LW, Baynes RE, Riviere JE, et al. Occurrence of flunixin residues in bovine milk samples from USA. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2013; 30: 1513–1516.
-
8. Lin Z. vahl Cl, Riviere JE. Human food safety implications of variation in food animal drug metabolism. Sci Rep 2016; 6: 27907.
-
9. FARAD. Extralabel drug use (ELDU) resource page. Available at: www.farad.org/eldu/eldumain.asp. Accessed Oct 4, 2016.
-
10. FDA. Guidance for industry #3. General principles for evaluating the human food safety of new animal drugs used in food-producing animals (Draft revised guidance). July 2016. Available at: www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndusGui/ucm052180.pdf. Accessed Oct 10, 2016.
-
11. FDA. Freedom of information summary, supplemental new animal drug application NADA 101–479, Banamine injectable solution (flunixin meglumine). www.fda.gov/downloads/animalveterinary/products/approvedanimaldrugproducts/foiadrugsummaries/ucm064905.pdf. Accessed Jul 10, 2012.
-
12. Tolerances for residues of new animal drugs in food. 21 CFR 556.
-
13. European Medicines Agency Committee for Veterinary Medicinal Products. Flunixin: summary report (1). 1999. Available at: www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014324.pdf. Accessed May 2, 2016.
-
14. FARAD. FARAD Newsletter 2007;9. Available at: www.farad.org/publications/newsletters/FARADNewsletter_9.pdf. Accessed Apr 29, 2016.
-
15. Smith GW, Davis JL, Tell LA, et al. Extralabel use of nonsteroidal anti-inflammatory drugs in cattle. J Am Vet Med Assoc 2008; 232: 697–701.
-
16. Leavens TL, Tell LA, Kissell LW, et al. Development of a physiologically based pharmacokinetic model for flunixin in cattle (Bos taurus). Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2014; 31: 1506–1521.
-
17. FDA. Animal Drugs @ FDA. Flunixin meglumine. Available at: www.accessdata.fda.gov/scripts/animaldrugsatfda/. Accessed May 2, 2016.
-
18. Merck Animal Health. Resflor Gold product information. Summit, NJ: Merck Animal Health, 2009.
-
19. Hannon SJ, Perrett T, Wildman BK, et al. Efficacy of a florfenicol-flunixin meglumine combination product versus tulathromycin or ceftiofur crystalline free acid for the treatment of undifferentiated fever in feedlot calves. Vet Ther 2009; 10: E1–E18.
-
20. Health Products Regulatory Authority. Finadyne transdermal summary of product characteristics. Available at: www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_10996-272-001_18092015141937.pdf. Accessed Oct 10, 2016.
-
21. Anderson KL, Neff-Davis CA, Davis LE, et al. Pharmacokinetics of flunixin meglumine in lactating cattle after single and multiple intramuscular and intravenous administrations. Am J Vet Res 1990; 51: 1464–1467.
-
22. Kissell LW, Smith GW, Leavens TL, et al. Plasma pharmacokinetics and milk residues of flunixin and 5-hydroxy flunixin following different routes of administration in dairy cattle. J Dairy Sci 2012; 95: 7151–7157.
-
23. Odensvik K, Johansson M. High-performance liquid chromatography method for determination of flunixin in bovine plasma and pharmacokinetics after single and repeated doses of the drug. Am J Vet Res 1995; 56: 489–495.
-
24. Lichtenwalner DM, Cameron BD, Young C. The metabolism and pharmacokinetics of flunixin meglumine in cows and steers, in Proceedings. 14th World Cong Dis Cattle 1986; 1179–1183.
-
25. Clement RP, Simmons RD, Christopher RJ, et al. Design and conduct of studies to meet residue chemistry requirements. In: Hutson DH, Hawkins DR, Paulson GD, et al, eds. Xenobiotics and food-producing animals: metabolism and residues. Washington, DC: American Chemical Society, 1992; 37–48.
-
26. Benitz AM. Pharmacology and pharmacokinetics of flunixin meglumine in the bovine, in Proceedings. 13th World Cong Dis Cattle 1984; 928–930.
-
27. Shelver WL, Tell LA, Wagner S, et al. Comparison of ELISA and LC-MS/MS for the measurement of flunixin plasma concentrations in beef cattle after intravenous and subcutaneous administration. J Agric Food Chem 2013; 61: 2679–2686.
-
28. Smith DJ, Shelver WL, Baynes RE, et al. Excretory, secretory, and tissue residues after label and extra-label administration of flunixin meglumine to saline- or lipopolysaccharide-exposed dairy cows. J Agric Food Chem 2015; 63: 4893–4901.
-
29. Landoni MF, Cunningham FM, Lees P. Determination of pharmacokinetics and pharmacodynamics of flunixin in calves by use of pharmacokinetic/pharmacodynamic modeling. Am J Vet Res 1995; 56: 786–794.
-
30. Lacroix MZ, Gayrard V, Picard-Hagen N, et al. Comparative bioavailability between two routes of administration of florfenicol and flunixin in cattle. Rev Med Vet (Toulouse) 2011; 162: 321–324.
-
31. Gatne MM, Yadav MH, Mahale TR. Pharmacokinetics of flunixin in buffalo calves after single intramuscular administration. Buffalo Bull 2012; 31: 214–218.
-
32. Odensvik K. Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers. J Vet Pharmacol Ther 1995; 18: 254–259.
-
33. Hardee GE, Smith JA, Harris SJ. Pharmacokinetics of flunixin meglumine in the cow. Res Vet Sci 1985; 39: 110–112.
-
34. FDA. Freedom of information summary, original new animal drug application NADA 141–229, Resflor gold (florfenicol and flunixin meglumine [in 2-pyrrolidone and triacetin] injectable solution). Available at: www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSuFOIADru/UCM203309.pdf. Accessed Oct 10, 2016.
-
35. Rantala M, Kaartinen L, Välimäki E, et al. Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. J Vet Pharmacol Ther 2002; 25: 251–258.
-
36. Pyörälä S, Laurila T, Lehtonen S, et al. Local tissue damage in cows after intramuscular administration of preparations containing phenylbutazone, flunixin, ketoprofen and metamizole. Acta Vet Scand 1999; 40: 145–150.
-
37. Fajt VR, Wagner SA, Pederson LL, et al. The effect of intramuscular injection of dinoprost or gonadotropin-releasing hormone in dairy cows on beef quality. J Anim Sci 2011; 89: 1939–1943.
-
38. Damian P, Craigmill AL, Riviere JE. Extralabel use of nonsteroidal anti-inflammatory drugs. J Am Vet Med Assoc 1997; 211: 860–861.
-
39. Feely WF, Chester-Yansen C, Thompson K, et al. Flunixin residues in milk after intravenous treatment of dairy cattle with (14)C-flunixin. J Agric Food Chem 2002; 50: 7308–7313.
-
40. FDA. Freedom of information summary, supplemental new animal drug application NADA 101–479, Banamine injectable solution (flunixin meglumine). Available at: www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm064910.pdf. Accessed Oct 10, 2016.
-
41. Ngoh MA, Wislocki PG, Thompson K, et al. Residue depletion study and withdrawal period for flunixin-N-methyl glucamine in bovine milk following intravenous administration. J Agric Food Chem 2003; 51: 4701–4707.
-
42. Kissell LW, Leavens TL, Baynes RE, et al. Comparison of pharmacokinetics and milk elimination of flunixin in healthy cows and cows with mastitis. J Am Vet Med Assoc 2015; 246: 118–125.
-
43. Elmas M, Yazar E, Uney K, et al. Pharmacokinetics of flunixin after intravenous administration in healthy and endotoxaemic rabbits. Vet Res Commun 2006; 30: 73–81.
-
44. Galbraith EA, McKellar QA. Protein binding and in vitro serum thromboxane B2 inhibition by flunixin meglumine and meclofenamic acid in dog, goat and horse blood. Res Vet Sci 1996; 61: 78–81.
-
45. Deyrup CL, Southern KJ, Cornett JA, et al. Examining the occurrence of residues of flunixin meglumine in cull dairy cows by use of the flunixin cull cow survey. J Am Vet Med Assoc 2012; 241: 249–253.
-
46. Hwang YH, Yun H. Effects of acute hepatic and renal failure on pharmacokinetics of flunixin meglumine in rats. Exp Anim 2011; 60: 187–191.
-
47. Sarwari AR, Mackowiak PA. The pharmacologic consequences of fever. Infect Dis Clin North Am 1996; 10: 21–32.
-
48. Monshouwer M, Witkamp RF. Cytochromes and cytokines: changes in drug disposition in animals during an acute phase response: a mini review. Vet Q 2000; 22: 17–20.
-
49. Lees P, Higgins AJ. Flunixin inhibits prostaglandin E2 production in equine inflammation. Res Vet Sci 1984; 37: 347–349.
-
50. Holcomb SS. Third-spacing: when body fluid shifts. Nursing 2008; 38: 50–53.
-
51. Wu H, Baynes RE, Leavens T, et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to capture individual animal variability in the prediction of flunixin withdrawal times in cattle. J Vet Pharmacol Ther 2013; 36: 248–257.
-
52. Merck Animal Health. Banamine-S (flunixin meglumine) injectable solution product bulletin. Summit, NJ: Merck Animal Health 2013.
-
53. Campler M, Pairis-Garcia MD, Stadler KJ, et al. Rubber mat placement in a farrowing and lactation facility: tips and techniques. J Swine Health Prod 2016; 24: 142–146.
-
54. Pluym LM, Van Nuffel A, van Weyenberg S, et al. Prevalence of lameness and claw lesions during different stages in the reproductive cycle of sows and the impact on reproduction results. Animal 2013; 7: 1174–1181.
-
55. Elmore MRP, Garner JP, Johnson AK, et al. A flooring comparison: the impact of rubber mats on the health, behavior, and welfare of group-housed sows at breeding. Appl Anim Behav Sci 2010; 123: 7–15.
-
56. Pairis-Garcia MD, Karriker LA, Johnson AK, et al. Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration. BMC Vet Res 2013; 9: 165.
-
57. Buur JL, Baynes RE, Smith GS, et al. Pharmacokinetics of flunixin meglumine in swine after intravenous dosing. J Vet Pharmacol Ther 2006; 29: 437–440.
-
58. Howard JT, Baynes RE, Brooks JD, et al. The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine. J Vet Pharmacol Ther 2014; 37: 531–541.
-
59. Gehring R, Baynes RE, Craigmill AL, et al. Feasibility of using half-life multipliers to estimate extended withdrawal intervals following the extralabel use of drugs in food-producing animals. J Food Prot 2004; 67: 555–560.
Advertisement
Avoiding violative flunixin meglumine residues in cattle and swine
Powered by PubFactory